+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Risk factors for recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia



Risk factors for recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia



Zhonghua Xue Ye Xue Za Zhi 40(1): 17-23



目的: 分析并探讨真性红细胞增多症(PV)和原发性血小板增多症(ET)患者发生再次血栓事件(再栓)的临床特点及危险因素。 方法: 回顾性分析首都医科大学附属北京安贞医院2001年2月至2016年11月诊治的38例发生再栓事件的ET和PV患者的临床资料,采用Logistic回归分析再栓事件危险因素。 结果: 共计104例首次血栓事件的ET和PV患者中,38例(36.5%)患者发生再栓,年发生率为9.8%/人,ET组、PV组再栓年发生率分别为12.3%/人、5.7%/人。再栓事件共56次,42.1%发生在首次血栓形成后1年内;动脉血栓症占97.4%(以急性冠脉综合征最为多见),静脉血栓症占2.6%。ET组再栓以急性冠脉综合征最多见(18例,64.3%),PV组以脑梗死最常见(7例,70.0%)。2次及以上再栓患者中,PV(9例,90.0%)明显多于ET(7例,25.0%)。再栓组初诊WBC>12.5×10(9)/L(52.6%对31.8%,P=0.036)、红细胞比容(Hct)>45%(50.0%对30.0%,P=0.046)、既往血栓史(86.8%对13.6%,P<0.001)、脾肿大(84.2%对33.3%,P<0.001)、治疗未缓解(52.6%对15.2%,P<0.001)、血栓事件分层高危患者占比(94.7%对53.0%,P<0.001)高于单次血栓组;Logistic回归分析显示,既往血栓史(OR=13.697,P=0.025)、脾肿大(OR=13.301,P=0.034)和血栓事件分层高危(OR=44.618,P=0.025)为ET/PV再栓的独立危险因素。 结论: ET和PV患者有较高的再栓发生率,ET患者再栓发生率高于PV患者,急性冠脉综合征多见;PV多次再栓发生率多于ET,脑梗死较多见。既往血栓史、脾肿大和血栓事件分层高危是再栓的独立危险预测因素。.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 066446341

Download citation: RISBibTeXText

PMID: 30704223


Related references

Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica 93(3): 372-380, 2008

Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia. American Journal of Hematology 85(2): 97-100, 2010

Recurrent Venous Thrombosis in Patients with Polycythemia Vera and Essential Thrombocythemia. Clinical Leukemia 1(6): 339-344, 2007

Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera. Cancer 115(24): 5740-5745, 2010

Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. Haematologica 92(1): 135-136, 2007

The risk of thrombosis in essential thrombocythemia and polycythemia vera. Seminars in Oncology 29(3 Suppl 10): 16-21, 2002

Risk of recurrent cardiovascular events in patients with Polycythemia Vera and Essential Thrombocythemia with a high PRV-1 mRNA level. Blood 102(11): 922a, November 16, 2003

High Risk of Deep Vein Thrombosis in Carriers of a Prothrombin-Gene Mutation in Patients with Polycythemia Vera and Essential Thrombocythemia. Blood 100(11): Abstract No 3144, November 16, 2002

Risk factors for non-melanoma skin cancer in patients with essential thrombocythemia and polycythemia vera. European Journal of Haematology 96(3): 285-290, 2016

New and treatment-relevant risk stratification for thrombosis in essential thrombocythemia and polycythemia vera. American Journal of Hematology 90(8): 683-685, 2015

Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. Leukemia Research 69: 100-102, 2018

Splenectomy after portal thrombosis in patients with polycythemia vera and essential thrombocythemia. Haematologica 87(11): 1180-1184, 2002

Leukocytosis in polycythemia vera and splenomegaly in essential thrombocythemia are independent risk factors for hemorrhage. European Journal of Haematology 90(3): 228-236, 2013

Prevention of thrombosis in polycythemia vera and essential thrombocythemia. Haematologica 93(3): 331-335, 2008

Prognostic risk model for patients with high-risk polycythemia vera and essential thrombocythemia. Expert Review of Hematology 11(3): 247-252, 2018